Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the champion biotech stocks to bargain according to Wall Street analysts. On December 4, Citi expert Yigal Nochomovitz reiterated a Buy standing connected Summit Therapeutics Inc. (NASDAQ:SMMT) and acceptable a $131.90 terms target.

The affirmative stance follows the Jefferies London Healthcare Conference 2025, during which the institution showcased its strategical advancements, including the improvement of ivonescimab, a caller PD-1/VEGF bispecific antibody. Ivonescimab has already been fixed to much than 3,000 patients successful objective trials and implicit 40,000 patients successful some commercialized and objective settings, including successful China, demonstrating its wide use.

The Harmony 3 survey continues to determination forward, with pivotal readouts expected successful 2026 and 2027, and a BLA filing for EGFR second-line therapy planned this quarter. Early objective information person been encouraging. The Harmoni 6 proceedings reported a hazard ratio of 0.60, a 40% betterment versus modular attraction successful squamous NSCLC, portion updated Harmony A results showed an wide endurance hazard ratio of 0.74. The squamous cohort of Harmony 3 is much than 80% enrolled and should decorativeness successful the archetypal fractional of 2026, with the non-squamous cohort expected to implicit aboriginal that year.

Summit has besides started a caller colorectal crab study, and its concern with Revolution Medicine aims to harvester ivonescimab with RAS inhibitors, with diligent dosing expected to statesman aboriginal adjacent year. PFS and interim endurance readouts planned for 2026 could further enactment ivonescimab’s imaginable relation successful crab treatment.

With much than $750M successful currency from caller financing, the institution says it has capable superior to enactment operations and cardinal milestones for the adjacent 12 to 18 months.

Summit Therapeutics Inc. (NASDAQ:SMMT) is simply a biopharmaceutical institution processing treatments for superior unmet aesculapian needs, chiefly successful oncology, with its pb drug, ivonescimab, a bispecific antibody.

While we admit the imaginable of SMMT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.